Carbamic acid, N-[6-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorophenyl]-1H-benzimidazol-2-yl]-, ethyl ester

Biological Activity

AMXI-5001 is a potent, orally active, and dual parp1/2 and microtubule polymerization inhibitor. MXI-5001 exhibits selective antitumor cytotoxicity across a wide variety of human cancer cells with much lower IC50s than existing clinical PARP1/2 inhibitors. AMXI-5001 induces complete regression of established tumors, including exceedingly large tumors[1].

References

[1]. Lemjabbar-Alaoui H, et al. AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers. Am J Cancer Res. 2020;10(8):2649-2676.